A Stanford-designed molecule turns a major lymphoma-promoting protein against cancer cells, activating their own self-destruct machinery instead of simply blocking tumor growth. In mice, the treatment completely eliminated aggressive human lymphoma tumors within 11 days, although much more testing is needed before it could reach patients.